Back to User profile » Dr Christian A. Gleissner

Papers published by Dr Christian A. Gleissner:


The influence of surgical technique on early posttransplant atrial fibrillation — comparison of biatrial, bicaval, and total orthotopic heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Erbel C, Gleissner CA, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO

Therapeutics and Clinical Risk Management 2017, 13:287-297

Published Date: 8 March 2017

Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2016, 10:677-686

Published Date: 16 February 2016

Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation

Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2015, 9:1217-1224

Published Date: 24 February 2015

Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2015, 9:93-102

Published Date: 17 December 2014

CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions

Akhavanpoor M, Gleissner CA, Gorbatsch S, Doesch AO, Akhavanpoor H, Wangler S, Jahn F, Lasitschka F, Katus HA, Erbel C

Drug Design, Development and Therapy 2014, 8:2359-2371

Published Date: 27 November 2014

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen

Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2014, 8:1307-1314

Published Date: 9 September 2014

Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions

Doesch AO, Zhao L, Gleissner CA, Akhavanpoor M, Rohde D, Okuyucu D, Hakimi M, Dengler TJ, Katus HA, Erbel C

Drug Design, Development and Therapy 2014, 8:447-457

Published Date: 12 May 2014

Conversion to generic cyclosporine A in stable chronic patients after heart transplantation

Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, Ruhparwar A, Ehlermann P, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:1421-1426

Published Date: 28 November 2013

Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study

Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA

Drug Design, Development and Therapy 2013, 7:1323-1328

Published Date: 5 November 2013

Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation

Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:297-303

Published Date: 8 April 2013

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients

Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA

Drug Design, Development and Therapy 2012, 6:289-295

Published Date: 12 October 2012